TBCOX2 - A phase I/II randomized trial on Safety and Immunogenicity of the Therapeutic H56:IC31 Vaccine and adjunctive Cyclooxygenase-2-inhibitor in patients with Tuberculosis

Date created: | Last Updated:

: DOI | ARK

Creating DOI. Please wait...

Create DOI

Category: Project

Description: This first-in-human randomized clinical trial at Oslo University Hospital, Norway on patients with tuberculosis shows that the vaccine H56:I31 developed by Statens Serum Institut is safe and immunogenic during active tuberculosis disease and could serve as host-directed-therapy to improve prognosis and combat the tuberculosis pandemic

Wiki

Add important information, links, or images here to describe your project.

Files

Loading files...

Citation

Recent Activity

Loading logs...

OSF does not support the use of Internet Explorer. For optimal performance, please switch to another browser.
Accept
This website relies on cookies to help provide a better user experience. By clicking Accept or continuing to use the site, you agree. For more information, see our Privacy Policy and information on cookie use.
Accept
×

Start managing your projects on the OSF today.

Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.